In a brief filed Monday, Amgen and Horizon argue that the U.S. District Court of Northern Illinois shouldn’t let the Federal Trade Commission (FTC) block their union over concerns that a dangerous monopoly on two blockbuster drugs will result.
Source: Drug Industry Daily